Replimune Group Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$297MTTM through 30 Jun 2026
Free Cash Flow -$280.5MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-188.9%ROE
-71.1%ROA
Balance Sheet Health
Debt / Equity0.50x
Current Ratio4.79x
Net Debt-$157.3Mnet cash position
Cash & Equivalents$185.4M
Quality Metrics
Altman Z-Score-5.32
Piotroski F-Score2 / 9
Earnings-Beat Rate25.0%
Multi-Year Trend
Diluted EPS-$3.15TTMFY2026: $-3.38
Dividend
No dividend
Capital Allocation
R&D Spend$212.6M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Oncolytic Immunotherapies | $0 | View detailsThe company is focused on advancing its clinical pipeline, including the confirmatory Phase 3 IGNYTE-3 trial for RP1 and the REVEAL Phase 2/3 trial for RP2. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.